Price
$8.27
Decreased by -0.84%
Dollar Volume (20D)
14.26 M
ADR%
4.7
Earnings Report Date (estimate)
Nov 1, 23 (-0.17)
Market Cap.
1.19 B
Shares Float
140.54 M
Shares Outstanding
143.42 M
Beta
1.25
Price / Earnings
-16.54
BPR
0.30
20D Range
7.97 10.24
50D Range
7.97 12.43
200D Range
4.07 12.43
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 3, 23 0.08
Increased by +132.00%
0.20
Decreased by -60.00%
May 4, 23 -0.18
Increased by +33.33%
-0.24
Increased by +25.00%
Feb 28, 23 -0.18
Increased by +28.00%
-0.27
Increased by +33.33%
Nov 3, 22 -0.06
Increased by +84.62%
-0.17
Increased by +64.71%
Aug 4, 22 -0.25
Increased by +32.43%
-0.22
Decreased by -13.64%
May 10, 22 -0.27
Increased by +32.50%
-0.27
Feb 28, 22 -0.25
Decreased by -400.00%
-0.27
Increased by +7.41%
Nov 3, 21 -0.39
Decreased by -39.29%
-0.33
Decreased by -18.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 41.49 M
Increased by +47.19%
-11.49 M
Increased by +67.64%
Decreased by -27.70%
Increased by +78.02%
Mar 31, 23 34.41 M
Increased by +59.12%
-26.21 M
Increased by +30.36%
Decreased by -76.16%
Increased by +56.23%
Dec 31, 22 28.43 M
Increased by +21.50%
-26.05 M
Increased by +21.84%
Decreased by -91.60%
Increased by +35.67%
Sep 30, 22 55.78 M
Increased by +280.30%
-8.99 M
Increased by +82.11%
Decreased by -16.12%
Increased by +95.30%
Jun 30, 22 28.19 M
Increased by +325.85%
-35.52 M
Increased by +24.45%
Decreased by -125.98%
Increased by +82.26%
Mar 31, 22 21.63 M
Increased by +2.27 K%
-37.63 M
Increased by +25.31%
Decreased by -174.01%
Increased by +96.84%
Dec 31, 21 23.40 M
Decreased by -53.22%
-33.32 M
Decreased by -47.73%
Decreased by -142.38%
Decreased by -215.80%
Sep 30, 21 14.67 M
Increased by +50.48 K%
-50.26 M
Decreased by -47.53%
Decreased by -342.64%
Increased by +99.71%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.